| Title： | Clinical practice China guidelines for breast cancer during pregnancy and lactation (2022 edition) |
| Edition： | Updated |
| Classification： | Standard guideline |
| Field： | Comprehensive guideline |
| Countries and regions： | China |
| Guidelines users： | Clinicians specializing in breast diseases in China. |
| Evidence classification method： | The level of evidence grading system was developed by referring to the GRADE system combined with findings in clinical studies in China. The levels are classified as Category I, II, III, and IV to quantify the evaluation of the reliability of the evidence by experts on the compiling committees. |
| Development unit： | Chinese Society of Breast Surgery, Chinese Society of Surgery, Chinese Medical Association |
| Registration time: | 2022-10-12 |
| Registration number： | PREPARE-2022CN646 |
| Purpose of the guideline: | To standardize the clinical diagnosis and treatment of breast cancer during pregnancy and lactation, based on the Clinical Practice Guidelines for Pregnancy-associated Breast Cancer (PABC): Chinese Society of Breast Surgery (CSBrS) Practice Guidelines 2021, the Chinese Society of Breast Surgery evaluated the level of evidence in clinical research of breast cancer during pregnancy and lactation by referring to Grading of Recommendations Assessment, Development and Evaluation (GRADE) system. Combined with the clinical characteristics of patients and accessibility of the clinical practice of breast surgery in China, the Clinical practice China guidelines for breast cancer during pregnancy and lactation (2022 edition) were created to provide reference for the clinical work of breast surgeons in China. |
Latest registration
